# Datar Cancer Genetics signs $250M contract with Artemis DNA

Datar Cancer Genetics announced a $250 million, 5-year exclusive agreement with Artemis DNA to provide Datar's cancer detection liquid biopsies in the USA and Vietnam markets. Artemis DNA will also provide testing facilities in Texas and California.

- Type: Contract
- Announced: 2022-05-11
- Where: Texas, California, United States
- Value: $250.0M
- Status: completed
- Products: Trucheck Pragma, Cancertrack, liquid biopsy cancer detection tests
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Datar Cancer Genetics](https://endata.com/companies/62804.md)
- [Artemis DNA](https://endata.com/companies/62805.md) (customer)

## Sources

- [biovoicenews.com](https://biovoicenews.com/datar-cancer-genetics-signs-us-250-million-contract-with-artemis-dna/), 2022-05-11: "We are extremely delighted to offer our highly accurate cancer detection technology for the benefit of patients in the USA and Vietnam in partnership with Artemis DNA."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.